



Correction to: Lomitapide – a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia

Claudia Stefanutti¹

Published online: 15 July 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Current Atherosclerosis Reports (2020)

<https://doi.org/10.1007/s11883-020-00858-4>

© The Author(s) 2020

Due to errors during galley proofing, the original version of this article has been corrected.

The following errors were corrected: page 4, paragraph 2, line 4, “week 126” is corrected to “week 246”; page 5, paragraph 1, line 2, “LDL” is corrected to “LDL-C”; page 5, paragraph 1, line 5, “absorbed” is corrected to “internalized”; page 6, paragraph 3, column 2, line 5, “from Spain” was corrected to “of an Hispanic female”; page 6, paragraph 5, line 13, “five” was corrected to “six”, and “two” was corrected to “three”; page 7, paragraph 2, line 4, “and no LA” was added after “20 mg/day”; page 7, paragraph 3, line 1, “a single” was corrected to “an”; Figure 1, “12-patient paediatric” should read “11-patient paediatric.” We also have p4 para 2 line 3 where 296 has been changed to 294, and same page, para 3, line 6 where we have added ‘Risk’ to Risk Management Plan.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s11883-020-00858-4>

✉ Claudia Stefanutti
claudia.stefanutti@uniroma1.it

¹ Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Regional Centre (Lazio) for Rare Diseases, Immunohematology and Transfusion Medicine, Department of Molecular Medicine, “Sapienza” University of Rome, “Umberto I” Hospital, Rome, Italy